Skip to main content

Table 2 Summarize of pretreatment NLR in each prostate cancer status

From: A high neutrophil-to-lymphocyte ratio is a poor prognostic factor for castration-resistant prostate cancer patients who undergo abiraterone acetate or enzalutamide treatment

Treatment n Journal
Pre and post DOC treatment 449 Current Study
Pre CBZ treatment 47 Uemura and Kawahara et al. Biomed Res Int. 2017
Initial metastatic prostate cancer 48 Kawahara and Yokomizo et al. BMC Cancer 2016
PSA 4 to 10 ng/mL 810 Kawahara and Fukui et al. Oncotarget 2015
  1. DOC Docetaxel, CBZ Cabazitaxel, PSA Prostate-specific antigen